<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844177</url>
  </required_header>
  <id_info>
    <org_study_id>NCPHOI-2021-02</org_study_id>
    <nct_id>NCT04844177</nct_id>
  </id_info>
  <brief_title>Total Lymphoid Irradiation Pre-HSCT in Severe Congenital Neutropenia</brief_title>
  <official_title>Pilot Prospective Clinical Study of Safety and Efficacy of Conditioning Regimen With Total Lymphoid Irradiation Before Allogeneic Hematopoietic Stem Cell Transplantation With TCRab/CD19 Graft Depletion in Severe Congenital Neutropenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe congenital neutropenia (SCN) is a group of primary immunodeficiencies caused by&#xD;
      distinct gene mutations and characterized by neutrophil maturation impairment, which leads to&#xD;
      neutropenia, predisposition to severe bacterial and fungal infections, and myeloid&#xD;
      malignancies. Granulocyte-colony stimulation factor is used for pathogenetic therapy,&#xD;
      however, no adequate response is seen in some patients.&#xD;
&#xD;
      The only curative option for SCN is hematopoietic stem cell transplantation (HSCT). An&#xD;
      indication for HSCT in SCN is: no adequate response to G-CSF therapy, or development of&#xD;
      malignancies, or found unfavorable mutations of SCN genes, leading to poor response to G-CSF&#xD;
      and high risk of malignant transformation.&#xD;
&#xD;
      One of the major peculiarities of HSCT in SCN is a high risk of graft failure. That was&#xD;
      described in few studies in SCN transplantation and was also observed in our SCN HSCT cohort.&#xD;
      We also consider the role of TCRab/CD19 graft depletion, which is routinely used in our&#xD;
      center for GVHD prophylaxis in increased risks of graft failure.&#xD;
&#xD;
      Another problem often observed in our patients is the relatively high risks of death of&#xD;
      infections, developed after graft failure.&#xD;
&#xD;
      Due to predominantly early HSCT graft failure development, non-sufficient immuablation is&#xD;
      presumed as the main reason for graft failure. Because of the low level of toxicity,&#xD;
      associated with TCRab/CD19 depletion usage, this strategy is planned to be used in the&#xD;
      current study. To increase an immunoablative potential of conditioning regimen in SCN, total&#xD;
      lymphoid irradiation will be studied in combination with myeloablative agents and standardly&#xD;
      used serotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 14, 2021</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years post HSCT</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>event free survival</measure>
    <time_frame>2 years post HSCT</time_frame>
    <description>events - death, graft failure, secondary malignancy, relapse of malignancy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of transplant related mortality</measure>
    <time_frame>2 years post HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of graft failure</measure>
    <time_frame>2 years post HSCT</time_frame>
    <description>non-engraftment, secondary graft rejection, severe non-reversible bone marrow failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of graft versus host disease</measure>
    <time_frame>2 years post HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with donor chimerism</measure>
    <time_frame>2 years post HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary malignancies</measure>
    <time_frame>2 years post HSCT</time_frame>
    <description>number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of engraftment</measure>
    <time_frame>100 days post HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of early severe organ toxicity</measure>
    <time_frame>100 days post HSCT</time_frame>
    <description>number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of infectious complications</measure>
    <time_frame>1 year after HSCT</time_frame>
    <description>infectious complication - CMV, EVB, ADV reactivation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Severe Congenital Neutropenia</condition>
  <condition>GATA2 Deficiency</condition>
  <arm_group>
    <arm_group_label>intervention/treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:&#xD;
Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)&#xD;
Cyclophosphamide 120 mg/kg (days -5, -4, -3)&#xD;
Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)&#xD;
Melphalan 180 mg/m2 (day -2)&#xD;
Rituximab 100 mg/m2 (day -1)&#xD;
Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>conditioning with TLI</intervention_name>
    <description>Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:&#xD;
Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)&#xD;
Cyclophosphamide 120 mg/kg (days -5, -4, -3)&#xD;
Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)&#xD;
Melphalan 180 mg/m2 (day -2)&#xD;
Rituximab 100 mg/m2 (day -1)&#xD;
Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0</description>
    <arm_group_label>intervention/treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical indications for HSCT in SCN: clinical diagnosis of SCN with (1) no adequate&#xD;
             response to G-CST therapy or (2) with malignant transformation or (3) unfavorable&#xD;
             mutations of known SCN genes&#xD;
&#xD;
          -  GATA2 deficiency&#xD;
&#xD;
          -  SCN patients age at HSCT 18 months - 21 years&#xD;
&#xD;
          -  GATA2 deficiency patients age at HSCT more than 10 years&#xD;
&#xD;
          -  Signed informed consent to participate in the study&#xD;
&#xD;
          -  Presence of HLA-matched unrelated or HLA-mismatched related donor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of HLA matched related donor in absence of pathologic SCN gene mutation&#xD;
&#xD;
          -  Inability to perform TCRab/CD19 graft depletion&#xD;
&#xD;
          -  Contraindications for HSCT due to patients somatic condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dmitry Balashov, MD, PhD</last_name>
    <phone>84956647078</phone>
    <email>Dmitriy.Balashov@fccho-moscow.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Laberko, MD</last_name>
    <phone>84956647078</phone>
    <phone_ext>6223</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HSCT department</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>Dmitry Balashov, MD, PhD</last_name>
      <phone>84956647078</phone>
      <email>Dmitriy.Balashov@fccho-moscow.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>GATA2 Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

